Fresenius Kabi Launches New Generic for the Treatment of Multiple Myeloma
2 May 2022 - - US-based health care company Fresenius Kabi has introduced Bortezomib for Injection, a new generic equivalent to Velcade in the US and the newest addition to the most comprehensive injectable oncology portfolio in the industry, the company said.

Fresenius Kabi Bortezomib for Injection is available in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous or intravenous use.

Fresenius Kabi Bortezomib for Injection is an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma.

Multiple myeloma represents nearly 2% of all new cancer cases in the US and is expected to double in 20 years.

Mantle cell lymphoma represents approximately 5% of all non-Hodgkin's lymphoma diagnoses annually, and there are approximately 4,000 new cases each year.

Fresenius Kabi offers more than 30 different oncology drugs in the US, and nearly 90 % are formulated, filled and finished in the US Bortezomib for Injection is the newest example of the company's commitment to investing "More in America."

This effort is focused on providing more supply, more science, more support and more care to its customers and the patients they serve in the US Fresenius Kabi has invested nearly USD 1bn to modernize and expand advanced US pharmaceutical production and distribution facilities.

Bortezomib for Injection, along with other oncology medicines, is part of the company's KabiConnect program, a recent expansion of its KabiCare patient support program that offers copay assistance to eligible US patients.

The program can lower out-of-pocket costs to as little as USD0 per month for eligible patients. To determine eligibility, patients should speak to their physician. Enrollment is a simple online process.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition.

The company's products and services are used to help care for critically and chronically ill patients. The company's US headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.